




HFpEF BREAKTHROUGHS: BREAKING THE 30-YEAR STALEMATE

THE HFpEF “IDENTITY CRISIS”



Heart contracts normally but is too stiff to fill.

THE NEW ERA OF EVIDENCE



~20% RISK REDUCTION VIA SGLT2i

EMPEROR-Preserved & DELIVER trials proved empagliflozin & dapagliflozin reduce heart failure hospitalizations.




FINERENONE'S 2024 BREAKTHROUGH

FINEARTS-HF trial: First non-SGLT2 therapy with clear benefit (reduced worsening HF events).

TRIAL NAME	THERAPY	PRIMARY OUTCOME
EMPEROR-Preserved	Empagliflozin	21% RRR in CV Death/HF Hosp.
DELIVER	Dapagliflozin	18% RRR in CV Death/HF Hosp.
FINEARTS-HF	Finerenone	Significant reduction in worsening HF events




Pathophysiology stems from microvascular inflammation and comorbidities, not neurohormonal activation.



THE HIGH-RISK PHENOTYPE

Typically older, female, obese patients with hypertension, AF, or diabetes.

DIAGNOSIS AS A GATEWAY



Using these algorithms is now critical.